Department of Interventional Medicine, Department of Ultrasound, Guangdong Provincial Key Laboratory of Biomedical Imaging, Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
State Key Laboratory of Physical Chemistry of Solid Surfaces, The MOE Laboratory of Spectrochemical Analysis & Instrumentation, The Key Laboratory for Chemical Biology of Fujian Province, and Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.
Biomater Sci. 2021 Dec 21;10(1):243-257. doi: 10.1039/d1bm01374b.
Arsenic trioxide (ATO, AsO), an active ingredient of traditional Chinese medicine, has been approved by the U.S. Food and Drug Administration as an effective therapeutic agent for acute promyelocytic leukemia (APL). However, the application of ATO in treating advanced solid tumors like hepatocellular carcinoma (HCC) is still restricted by limited therapeutic efficacy and insufferable side effects. To solve this problem, we reported a general and facile strategy using human serum albumin (HSA) as a template for synthesizing a series of ATO-based nanoparticles with uniform single-albumin size. Then, we prepared a multifunctional drug delivery system (MDDS) based on MnAs/HSA termed MnAs/ICG/HSA-RGD, and tested its efficacy both and . Our results revealed that the photothermal effect of MnAs/ICG/HSA-RGD can not only cause irreversible damage to the tumor but also accelerate the discharge of As and Mn ions, enabling responsive chemotherapy and magnetic resonance imaging. Interestingly, the expression of HSP90, vimentin, and MMP-9 in tumor cells was inhibited during the treatment, resulting in less metastasis and recurrence. Moreover, no apparent side effect has been observed during the treatment. Therefore, MnAs/ICG/HSA-RGD can be considered as a promising option for HCC with excellent therapeutic efficacy and minimum side effects.
三氧化二砷（ATO，As2O3）是一种中药的有效成分，已被美国食品和药物管理局批准为治疗急性早幼粒细胞白血病（APL）的有效治疗药物。然而，ATO 应用于治疗肝癌（HCC）等晚期实体瘤仍受到疗效有限和难以忍受的副作用的限制。为了解决这个问题，我们报告了一种使用人血清白蛋白（HSA）作为模板合成一系列具有均匀单一白蛋白大小的 ATO 基纳米粒子的通用简便策略。然后，我们制备了一种基于 MnAs/HSA 的多功能药物递送系统（MDDS），称为 MnAs/ICG/HSA-RGD，并测试了其在体内和体外的疗效。我们的结果表明，MnAs/ICG/HSA-RGD 的光热效应不仅能导致肿瘤不可逆损伤，还能加速 As 和 Mn 离子的释放，实现响应性化疗和磁共振成像。有趣的是，在治疗过程中肿瘤细胞中 HSP90、波形蛋白和 MMP-9 的表达受到抑制，从而减少转移和复发。此外，在治疗过程中未观察到明显的副作用。因此，MnAs/ICG/HSA-RGD 可作为 HCC 治疗的一种有前途的选择，具有良好的疗效和最小的副作用。
